R1 RCM — Q2 2022 Earnings Presentation
10 slides from R1 RCM's earnings presentation, Aug 3, 2022
Slide 1: Second Quarter 2022 Earnings Call
August 3, 2022 Second Quarter 2022 Earnings Call NEED NEW IMAGE THAT WE SENT Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking
Slide 3: Second Quarter 2022 Results and Financial Outlook
3 Second Quarter 2022 Results and Financial Outlook Revenue and Adjusted EBITDA at the high end of ranges communicated on the June 27th guidance update call Revenue of $391.9 million, up $38.5 million or 10.9% compared to the same period last year GAAP net loss of $20.4 million, compared to net
Slide 4: CEO's Update
4 CEO’s Update 1. Deep focus on revenue intelligence significantly expands our capabilities; positions us to extend our competitive advantage 2. Blue chip installed base serves not only as an excellent reference base, but also as a source of potential new end-to-end wins 3. Modular sales engine unlo
Slide 5: President's Update
5 President’s Update Strong first half with revenue and Adjusted EBITDA ahead of full year goals Cloudmed’s platform delivers value to R1 and our customers by: Leveraging the algorithms and AI inherent in the Cloudmed platform Accelerating our technology innovation cycle Providing necessar
Slide 6: Q2'22 Non-GAAP Results – Q/Q and Y/Y Comparison
6 Q2’22 Non-GAAP Results – Q/Q and Y/Y Comparison Note1: Adjusted Cost of Services, Adjusted SG&A expense, and Adjusted EBITDA are non-GAAP measures. A reconciliation of non-GAAP to GAAP measures is provided in the Appendix of this presentation. ($ in millions) Q2'22 Q1'22 Q2'21 Key change driver(s)
Slide 7: Additional Commentary
7 Additional Commentary Cash and cash equivalents of $163.5 million as of 6/30/2022, compared to $123.9 million as 3/31/2022 - Cash use of $96.4 million for operations in Q2, primarily due to Cloudmed-related transaction costs Balance sheet and liquidity position remain strong - Net debt1 of $1.
Slide 8: Appendix
8 Appendix
Slide 9: Use of Non-GAAP Financial Measures
9 Use of Non-GAAP Financial Measures 2022 GAAP Operating Income Guidance $55-65 Plus: Depreciation and amortization expense $160-165 Share-based compensation expense $80-85 Strategic initiatives, severance and other costs $165-175 Adjusted EBITDA Guidance $470-480 Reconciliation of GAAP Operating In
Slide 10: Reconciliation of Non-GAAP Financial Measures
10 Reconciliation of Non-GAAP Financial Measures $ in millions Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA Reconciliation of GAAP SG&A to Non-GAAP SG&A Reconciliation of GAAP Cost of Services to Non-GAAP Cost of Services Note1: Other costs are comprised of strategic initiatives cos